Zobrazeno 1 - 10
of 4 411
pro vyhledávání: '"BRAF Mutation"'
Autor:
Daisuke Uno, Kazuhira Endo, Tomomi Yoshikawa, Nobuyuki Hirai, Eiji Kobayashi, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki
Publikováno v:
Thyroid Research, Vol 17, Iss 1, Pp 1-9 (2024)
Abstract Introduction Activation of the MAPK pathway by genetic mutations (such as BRAF and RET) initiates and accelerates the growth of papillary thyroid carcinoma (PTC). However, the correlation between genetic mutations and clinical features remai
Externí odkaz:
https://doaj.org/article/c9b65364cc504a00b68c1590d7d2b76e
Autor:
Justin Lee, BA, Sabitha Sasidharan Pillai, MD, Avani Ganta, MD, Chanika Phornphutkul, MD, Jose Bernardo Quintos, MD
Publikováno v:
AACE Clinical Case Reports, Vol 10, Iss 5, Pp 174-178 (2024)
Background/Objective: We present an adolescent male with Noonan syndrome (NS) and celiac disease (CD) who attained normal adult height with growth hormone (GH) treatment and gluten-free diet (GFD). Case Report: A 15 ½ year old healthy male presented
Externí odkaz:
https://doaj.org/article/c9e11aa527234ae7a6f1d43ebbe7f65c
Autor:
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, T. A. Juratli
Publikováno v:
Acta Neuropathologica Communications, Vol 12, Iss 1, Pp 1-12 (2024)
Abstract Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here,
Externí odkaz:
https://doaj.org/article/0fb644eeacee4ed68b3f90f56d2e1371
Autor:
Ana-Maria Sigarteu Chindris, Michael Rivera, Yaohua Ma, Asha Nair, Yi Liu, Xue Wang, Brian M. Necela, Jennifer M. Kachergus, John D. Casler, Christopher Brett, Ana M. Rivas Mejia, Victor J. Bernet, John A. Copland, Keith L. Knutson, E. Aubrey Thompson, Robert C. Smallridge
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
IntroductionBRAFV600E mutation (BRAFmut) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERTmut) in the presence of BRAFmut (BRAFmutpTERTmut) has been demonstrated to conf
Externí odkaz:
https://doaj.org/article/4e35f5bc00f842e1a5836ad9a262635a
Autor:
Nina Yu, Osama A Raslan, Han Sung Lee, Brett J Theeler, Tarek A Raafat, Ruben Fragoso, Kiarash Shahlaie, Orwa Aboud
Publikováno v:
CNS Oncology, Vol 13, Iss 1 (2024)
Craniopharyngiomas are tumors that arise from the remnants of Rathke's pouch along the nasopharynx to the diencephalon. Current standard of care includes maximal surgical resection versus adjuvant radiation if a maximal resection is unfeasible. Pharm
Externí odkaz:
https://doaj.org/article/09dd43d1edc14fe381c10ed15a3bd736
Autor:
Anne Hansen Ree, Eirik Høye, Ying Esbensen, Ann-Christin R. Beitnes, Anne Negård, Linn Bernklev, Linn Kruse Tetlie, Åsmund A. Fretland, Hanne M. Hamre, Christian Kersten, Eva Hofsli, Marianne G. Guren, Halfdan Sorbye, Hilde L. Nilsen, Kjersti Flatmark, Sebastian Meltzer
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
The randomized METIMMOX trial (NCT03388190) examined if patients with previously untreated, unresectable abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC) might benefit from potentially immunogenic, short-course oxaliplati
Externí odkaz:
https://doaj.org/article/a08572504c1241d5a365f6b0a359ede1
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Papillary craniopharyngiomas are rare tumors prevalent to the precision oncology world due to their high rate of BRAF V600E mutations. Symptoms include vision loss, neuroendocrine dysfunction, and cognitive dysfunction. Treatment involves an interdis
Externí odkaz:
https://doaj.org/article/b4a741bb71e247abb31e82558ed854ab
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. EGFR tyrosine inhibitors are the preferred first-line treatment for patients with epidermal growth factor-cell receptor mutant (EGFR mutant) advanced NSCLC. Unfor
Externí odkaz:
https://doaj.org/article/c240e7fda61541daa0fbe059229966dc
Autor:
Lovisa Falkman, Anders Sundin, Britt Skogseid, Johan Botling, Yvette Bernardo, Göran Wallin, Liang Zhang, Staffan Welin, Ieva Lase, Kazhan Mollazadegan, Joakim Crona
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-7 (2024)
Background: Metastatic neuroendocrine carcinoma (NEC) is associated with short survival. Other than platinum-based chemotherapy, there is no clear standard regimen. Current guidelines suggest that combination treatment with BRAF-inhibitors should be
Externí odkaz:
https://doaj.org/article/e138f2357a1d4fe5ade89d82ea78a815
Autor:
Yanwei Chen, Shuangshuang Zhao, Zheng Zhang, Zheming Chen, Bingxin Jiang, Maohui An, Mengyuan Shang, Xincai Wu, Xin Zhang, Baoding Chen
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
PurposePapillary thyroid carcinoma (PTC) frequently coexists with Hashimoto’s thyroiditis (HT), which poses challenges in detecting central lymph node metastasis (CLNM) and determining optimal surgical management. Our study aimed to identify the in
Externí odkaz:
https://doaj.org/article/5c3a00a9c5134b168b47ee47c9943ba0